BTIG Research Reiterates Buy Rating for Outset Medical (NASDAQ:OM)

Outset Medical (NASDAQ:OM)‘s stock had its “buy” rating restated by research analysts at BTIG Research in a note issued to investors on Tuesday,Benzinga reports. They currently have a $17.00 price target on the stock. BTIG Research’s price target suggests a potential upside of 350.93% from the company’s previous close.

Several other brokerages have also weighed in on OM. Royal Bank Of Canada dropped their target price on Outset Medical from $22.00 to $17.00 and set a “sector perform” rating on the stock in a research report on Tuesday, November 11th. Stifel Nicolaus set a $14.00 price target on Outset Medical and gave the company a “buy” rating in a research note on Tuesday, November 11th. Weiss Ratings restated a “sell (e+)” rating on shares of Outset Medical in a report on Monday, December 8th. Finally, Wall Street Zen upgraded shares of Outset Medical from a “sell” rating to a “hold” rating in a research note on Saturday, December 13th. One research analyst has rated the stock with a Strong Buy rating, two have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average target price of $12.67.

Outset Medical Trading Down 3.8%

NASDAQ OM opened at $3.77 on Tuesday. The company has a current ratio of 7.09, a quick ratio of 5.77 and a debt-to-equity ratio of 0.69. Outset Medical has a 1-year low of $3.66 and a 1-year high of $25.35. The firm’s fifty day simple moving average is $8.67 and its 200-day simple moving average is $13.75. The company has a market capitalization of $68.43 million, a PE ratio of -0.29 and a beta of 2.03.

Institutional Inflows and Outflows

Institutional investors and hedge funds have recently bought and sold shares of the company. Legal & General Group Plc acquired a new stake in shares of Outset Medical in the second quarter valued at about $34,000. Ameritas Investment Partners Inc. acquired a new position in shares of Outset Medical during the 2nd quarter worth about $35,000. BNP Paribas Financial Markets boosted its stake in Outset Medical by 7,013.8% during the 2nd quarter. BNP Paribas Financial Markets now owns 2,063 shares of the company’s stock valued at $40,000 after purchasing an additional 2,034 shares during the period. Police & Firemen s Retirement System of New Jersey acquired a new stake in Outset Medical in the 2nd quarter valued at approximately $78,000. Finally, New York State Common Retirement Fund acquired a new stake in Outset Medical in the 2nd quarter valued at approximately $108,000.

Outset Medical Company Profile

Outset Medical, Inc, a medical technology company, engages in the development of a hemodialysis system for hemodialysis in the United States. The company offers Tablo Hemodialysis System, a compact console with integrated water purification, on-demand dialysate production, and software and connectivity capabilities for dialysis care in acute and home settings; and manufactures, supports, and distributes for Tablo console, Tablo cartridge, and other consumables.